Filed Pursuant to Rule 424(b)(3)
                                                Registration No. 333-59798


                              Prospectus Supplement
                      (To Prospectus Dated January 8, 2002)

     Prospective  investors  should  read  this  prospectus  supplement  and the
related  prospectus  carefully  before  investing in the common stock of CEL-SCI
Corporation.  Both documents contain  information  prospective  investors should
consider when making an investment decision.

     The attached  prospectus  relates to the resale of shares  acquired by Paul
Revere  Capital  Partners  pursuant to the equity line of credit.  Because  Paul
Revere Capital Partners may sell some or all of these shares,  and because there
are currently no agreements,  arrangements or understandings with respect to the
sale of any of these shares, CEL-SCI cannot estimate the actual number of shares
that Paul  Revere  Capital  Partners  will  hold  after  the  completion  of the
offering.

      The following provides information concerning the first three drawdowns
requested by CEL-SCI.

 Date of       Shares          Average Sale             Net Proceeds
  Sale         Sold          Price Per Share            to Cel-Sci
--------       -----          ---------------         ------------------

11/09/01      277,684             $1.08                  $299,000
01/08/02      333,993             $0.87                  $290,404
02/06/02      288,377             $0.81                  $234,000


     CEL-SCI's  common stock is quoted on the American  Stock Exchange under the
symbol  "CVM."  On  February  5,  2002 the  closing  price  for one share of the
CEL-SCI's common stock was $0.83.

     CEL-SCI  expects  to use the  proceeds  from the sale of these  shares  for
general and administrative expenses, research, and clinical trials.

           The date of this prospectus supplement is February 6, 2002.